Using a much larger data set than previously reported (UAMS n=1621), we confirmed an increase in the expression of EZH2 mRNA as myeloma progresses with the highest expression in symptomatic myeloma (MGUS vs MM adjusted P<0.00001, smouldering multiple myeloma (SMM) vs MM adjusted P<0.00001, MGUS vs SMM not significant; Figure 1a). This evidence concerns the gene EZH2 and Miyoshi myopathy.